clinical trial · NCT05644977
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
AbbVie·phase1·completed·n = 17
Healthy ParticipantsAlzheimer's Disease DementiaEmraclidinePlacebo
brief summary
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
started
Dec 2, 2022
primary completion
Apr 14, 2025
completion
Apr 14, 2025
last updated
May 2, 2025
official title
A Phase 1, Randomized, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Emraclidine Following Multiple Oral Doses in Healthy Elderly Participants (Part A) and to Evaluate the Safety and Tolerability of Emraclidine in Participants With Dementia Due to Alzheimer's Disease (Part B)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol